Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.38 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495463 | 0.89 | MLLT3 (0.37) | KDM4EMLLT3MLLT1 | |
| SCHEMBL2493245 | 0.87 | MLLT3 (0.36) | KDM4EMLLT3MLLT1 | |
| SCHEMBL2497581 | 0.85 | HSD17B14 (0.39) | KDM4EMLLT3MLLT1 | |
| SCHEMBL2497610 | 0.85 | SCN9A (0.35) | MLLT3MLLT1 | |
| SCHEMBL2498898 | 0.85 | KDM4C (0.36) | MLLT3MLLT1 | |
| SCHEMBL1877848 | 0.84 | NOTUM (0.54) | — | |
| SCHEMBL2494711 | 0.84 | TRPM8 (0.38) | MLLT3MLLT1 | |
| SCHEMBL2493286 | 0.84 | MGLL (0.34) | MLLT3MLLT1 | |
| SCHEMBL2497600 | 0.84 | KMT2A (0.35) | KDM4EMLLT3MLLT1 | |
| SCHEMBL2495838 | 0.84 | SCN9A (0.35) | KDM4EMLLT3MLLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209597-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA ALPHA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2009-08-20 | — | — | US | claimed |
| US-8030339-B2 | Imidazole derivatives for the treatment of anxiety and related diseases | NEUROSEARCH A/S (DK) | 2011-10-04 | — | — | US | disclosed |
| US-7939556-B2 | Imidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-05-10 | — | — | US | disclosed |
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | US | disclosed |
| US-20090209597-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA ALPHA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2009-08-20 | — | — | US | disclosed |
| EP-1940822-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX | NeuroSearch A/S (DK) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007042545-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209597-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA ALPHA RECEPTOR COMPLEX | GABRB1, GABRB2, GABRB3 | KDM4E 2635/4885MLLT3 3838/4885MLLT1 4058/4885 |
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | GABBR1, GABRB2, GABRB3 | KDM4E 2002/4885MLLT3 3352/4885MLLT1 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.